Reduced p-MLC2 after ROCKi impaired survival of sensitive and BRAFi-resistant melanoma pairs (A375, WM983A, WM983B, WM88) (Figures 3G, 3H, and S3A–S3C). Here, ROCK1 is linked to melanoma.